In human trials now for a treatment for HEP C (efficacy also demonstrated against HIV but HEP C is worth more). Synergistic efficacy demonstrated at 100% in vitro. Current trials, if successful, will lead to a serious re-rating (at least +100%). Trial results due before year end.
MC $12m, HEP C market expected to be $10b if a viable treatment emerges. Do the math and remember it is in the highest risk category! No toxicity to date in previous human trials, full efficacy demonstrated in cell cultures. Potential platform drug with modeled use against influenza, Dengue, and more.
